Immune response to polio vaccination in bone marrow transplant recipients. 1991

D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel.

Following a small outbreak of poliomyelitis which occurred in the summer of 1988 in Israel, two sequential doses of inactivated polio vaccine (IPV) were administered to 42 bone marrow transplant (BMT) recipients (aged 2-50 years) who were 6-96 months (median 16 months) after transplantation. Prior to vaccination, only 68-80% patients (n = 42) had protective (greater than or equal to 4) antibody levels against the three serotypes of poliovirus, compared with 92-96% (n = 25) before BMT (p = 0.02 for types 1 and 3). After the second dose of IPV, 89-98% (n = 27) of the recipients had protective antibody levels. The pre-vaccination antibody titers were lower than before BMT (p = 0.006, 0.0007 and 0.0008 for types 1,2 and 3, respectively). After the first dose of IPV, antibody titers rose in the 42 patients (p = 0.002, 0.043 and 0.002 for types 1, 2 and 3, respectively) and following the second dose, a further increase in antibody levels was noted. Regression analysis revealed that graft-versus-host disease, pre-BMT polio antibody titers, age and type of transplantation (allogeneic versus autologous) were significant explanatory variables for the specific antibody levels, while the time lapse between BMT and vaccination, and primary disease proved of no significance. Vaccination against poliovirus after BMT is advocated, as it reinstates and raises the lost specific humoral immunity.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
April 2005, Bone marrow transplantation,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
October 2002, Medicina clinica,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
July 1982, Annals of internal medicine,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
August 1990, Clinical and experimental immunology,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
October 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
October 2023, Vaccines,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
May 1997, Bone marrow transplantation,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
March 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
April 2000, Critical reviews in oncology/hematology,
D Engelhard, and R Handsher, and E Naparstek, and I Hardan, and N Strauss, and M Aker, and R Or, and H Baciu, and S Slavin
April 1984, Seminars in hematology,
Copied contents to your clipboard!